Original articles

Analysis of clinical and imaging manifestations in 8 patients with MOGAG and literature review

Expand
  • 1a. Department of Neurology, 1b. Department of Psychiatry, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    2. Department of Neurology, First People′s Hospital of Tianshui, Gansu Province, Gansu Tianshui 741000, China

Received date: 2022-04-18

  Online published: 2023-01-29

Abstract

Objective: To analyze the clinical manifestations, imaging features and prognosis of the patients with anti-myelin oligodendrocyte glycoprotein-IgG associated disorders (MOGAD). Methods: The data of eight MOGAD patients diagnosed in our hospital from January 2018 to December 2021 was analyzed, including the pathogenic factors, onset forms, clinical manifestations and auxiliary examinations. The therapeutic effect and prognosis of the patients were observed and discussed, and the relevant literatures were reviewed. Results: Among 8 patients with MOGAD, 6 were male and 2 were female, and the average age was 27.37 years. The most common clinical manifestations were limb weakness, limb twitching and blurred vision. The spinal puncture showed that the CSF pressure of the patients were 95-225 mmH2O. It revealed that 3 cases had increased CSF pressure, 5 cases had increased CSF cell count and 4 cases had increased CSF protein, while the CSF sugar and chloride were all normal. Six patients had positive MOG antibody in blood and cerebrospinal fluid. Five cases were found to have abnormal brain evoked potentials, and 4 cases had abnormal electroencephalogram. The brain MRI showed that the wide area of brain was affected, including different degree of abnormal signals in optic nerve, pons arm, thalamus, paraventricular, corpus callosum, frontal lobe, parietal lobe, occipital lobe, subcortical, cerebellum and other parts. Seven patients showed intracranial lesions, while only one patient showed abnormal signals in the long segment of cervical and thoracic spinal cord. All 8 patients were treated with high-dose methylprednisolone pulse therapy, in which 3 cases were given methylprednisolone combined with gamma globulin, and 1 case was treated with methylprednisolone combined with cyclophosphamide. After regular treatment, 7 patients were followed up for 3 years. The symptoms were relieved in 7 patients, while 1 patient still had recurrent attacks. By searching CNKI, CSPD,and CSTJD and PubMed Databases, 161 patients with MOGAD were enrolled. After reviewing the relevant literatures, it revealed that the subacute and chronic onset of MOGAD was common, and its clinical manifestations were diverse. The imaging study showed that the whole brain and spinal cord could be affected, and the recurrence rate was 30.00%-43.39%. The MOGAD patients were sensitive to hormone and immune therapy. The clinical and imaging manifestations and treatment prognosis of 8 MOGAD cases were consistent with previous report. Conclusions: The subacute and chronic onset of MOGAD is common, and most of the patients are young, and the patients show diverse clinical manifestations. In MOGAD patients, the routine examination of cerebrospinal fluid is non-specific, while the imaging of the whole brain and spinal cord are abnormal, and the damage area could be widely. The patients with MOGAD are sensitive to hormone and immune therapy, which presents satisfied therapeutic effects and prognosis. For the suspected patients, MOG should be performed as early as possible, and the multiple tests can be performed to avoid missed diagnosis.

Cite this article

LIN Xia, GAO Chao, HUANG Pei, WANG Gang, LIN Guozhen, REN Rujing . Analysis of clinical and imaging manifestations in 8 patients with MOGAG and literature review[J]. Journal of Diagnostics Concepts & Practice, 2022 , 21(05) : 606 -612 . DOI: 10.16150/j.1671-2870.2022.05.010

References

[1] 卢逸舟, 陈晟. 自身免疫性脑炎的诊断进展[J]. 重庆医科大学学报, 2021, 46(7):754-759.
[1] Lu YZ, Chen Shen. Diagnosis progress of autoimmune encephalitis[J]. J Chongqing Med Univ, 2021, 46(7):754-759.
[2] 中国免疫学会神经免疫分会. 抗髓鞘少突胶质细胞糖蛋白免疫球蛋白G抗体相关疾病诊断和治疗中国专家共识[J]. 中国神经免疫学和神经病学杂志, 2020, 27(2):86-95.
[2] Neuroimmunology Branch of Chinese Society for Immunology. Chinese expert consensus on diagnosis and treatment of MOG-IgG associated disorder[J]. Chin J Neuroimmunol Neurol, 2020, 27(2):86-95.
[3] 武国良, 彭涛. 抗髓鞘少突胶质细胞糖蛋白IgG抗体相关疾病20例临床分析[J]. 临床神经病学杂志, 2021, 34(6):422-426.
[3] Wu GL, Peng T. Clinical analysis of 20 cases of anti-myelin oligodendrocyte glycoprotein-IgG antibody asso-ciated diseases[J]. J Clin Neurol, 2021, 34(6):422-426.
[4] 刘慧勤, 崔红培, 张弥兰, 等. 髓鞘少突胶质细胞糖蛋白抗体相关疾病的临床、影像及预后特点[J]. 中华神经医学杂志, 2022, 21(2):164-171.
[4] Liu HQ, Cui HP, Zhang ML, et al. Clinical and imaging features and prognoses of myelin oligodendrocyte glycoprotein antibody associated disorders[J]. Chin J Neuromed, 2022, 21(2):164-171.
[5] 崔东清, 左瑶, 刘燕霞, 等. 髓鞘少突胶质细胞糖蛋白抗体相关疾病的临床及影像学特点[J]. 中华神经科杂志, 2020, 53(1):19-24.
[5] Cui DQ, Zuo Y, Liu YX, et al. The clinical and radiological features of myelin oligodendrocyte glycoprotein antibody associated disease[J]. Chin J Neuromed, 2020, 53(1):19-24.
[6] Lei X, Guo S, Cui S, et al. Clinical profile and treatment outcome in MOGAD: a single-center case-series study in Guiyang, China[J]. Front Neurol, 2022, 13:830488.
[7] Brill L, Ganelin-Cohen E, Dabby R, et al. Age-related clinical presentation of MOG-IgG seropositivity in Israel[J]. Front Neurol, 2021, 11:612304.
[8] Cobo-Calvo A, Ruiz A, Maillart E, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study[J]. Neurology, 2018, 90(21):e1858-e1869.
[9] Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease[J]. Nat Rev Neurol, 2019, 15(2):89-102.
[10] 周少旦, 付桔, 卜秀群, 等. 17例髓鞘少突胶质细胞糖蛋白抗体相关疾病患者的临床分析[J]. 中风与神经疾病杂志, 2020, 37(12):1105-1108.
[10] Zhou SD, Fu J, Bu XQ, et al. The clinical features of 17 patients with the myelin oligodendrocyte glycoprotien antibody-associated disease[J]. J Apoplexy Nerv Dis, 2020, 37(12):1105-1108.
[11] Wynford-Thomas R, Jacob A, Tomassini V. Neurological update: MOG antibody disease[J]. J Neurol, 2019, 266(5):1280-1286.
[12] Waters P, Fadda G, Woodhall M, et al. Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes[J]. JAMA Neurol, 2020, 77(1):82-93.
[13] Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing[J]. J Neuroinflammation, 2018, 15(1):134.
[14] Salama S, Khan M, Shanechi A, et al. MRI differences between MOG antibody disease and AQP4 NMOSD[J]. Mult Scler, 2020, 26(14):1854-1865.
[15] 尹翮翔, 张遥, 徐雁, 等. MOG抗体相关脑炎临床特点与预后分析[J]. 中国神经免疫学和神经病学杂志, 2021, 28(4):288-292,322.
[15] Yin HX, Zhang Y, Xu Y, et al. Clinical manifestations and prognosis of MOG-IgG associated encephalitis based on single-centered cohort data[J]. Chin J Neuroimmunol Neurol, 2021, 28(4):288-292,322.
[16] Akaishi T, Sato DK, Takahashi T, et al. Clinical spectrum of inflammatory central nervous system demyelina-ting disorders associated with antibodies against myelin oligodendrocyte glycoprotein[J]. Neurochem Int, 2019, 130:104319.
[17] 张包静子, 周磊, 汪亮, 等. 髓鞘少突胶质细胞糖蛋白抗体相关脊髓炎临床特点分析[J]. 中华医学杂志, 2020, 100(5):334-338.
[17] Zhang BJZ, Zhou L, Wang L, et al. Clinical characteristics of myelin oligodendrocyte glycoprotein antibody associated myelitis[J]. Natl Med J China, 2020, 100(5):334-338.
[18] Bartels F, Lu A, Oertel FC, et al. Clinical and neuroimaging findings in MOGAD-MRI and OCT[J]. Clin Exp Immunol, 2021, 206(3):266-281.
[19] Shahriari M, Sotirchos ES, Newsome SD, et al. MOGAD: how it differs from and resembles other neuroinflammatory disorders[J]. AJR Am J Roentgenol, 2021, 216(4):1031-1039.
[20] de Mol CL, Wong Y, van Pelt ED, et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults[J]. Mult Scler, 2020, 26(7):806-814.
[21] Chen JJ, Bhatti MT. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis[J]. Curr Opin Neurol, 2020, 33(1):47-54.
[22] Hyun JW, Kwon YN, Lee HL, et al. Recurrence of clinical events at the same anatomical location in patients with MOG antibody-associated disease[J]. Mult Scler, 2021, 27(3):449-452.
[23] Derdelinckx J, Reynders T, Wens I, et aI. Cells to the rescue: emerging cell-based treatment approaches for NMOSD and MOGAD[J]. Int J Mol Sci, 2021, 22(15):7925.
Outlines

/